Shockwave and Pulsed Electromagnetic Fields for Erectile Function
what works, how much, and on what protocol

September 2026 · 9 min read · Clinical Evidence Review

Bottom line: Two different technologies are discussed here — shockwave (Li-ESWT), which is an acoustic pressure wave, and PEMF, which is a magnetic field. Their numbers are not transferable, and every figure on this page is labelled with the technology it was measured on. The largest and most recent meta-analysis in the field — 32 randomized controlled trials, 1,986 patients, September 2025 — found that micro-energy treatments, including electromagnetic fields, improved erectile function at 1, 3, 6 and 12 months, and that no significant difference in efficacy was found between energy types (PubMed 41047356). In the same work: treatment twice weekly outperformed once weekly (p<0.05), and a course of no more than four weeks was the recommended protocol. The only sham-controlled trial with erection as its primary endpoint on a pulsed electromagnetic field device produced a 6.9-point difference on the IIEF — above the 4-point threshold a patient can feel — against 3.89 points for shockwave in the July 2025 Cochrane review, which did not clear it (PubMed 40654049).

What Is Shockwave Therapy for Erectile Function, and How Does It Differ From PEMF?

Low-intensity shockwave therapy delivers focused acoustic pressure waves, while PEMF delivers a changing magnetic field — two entirely different physical families, at different intensities, aimed at different mechanisms. Li-ESWT transmits mechanical pressure waves into the tissue; the mechanistic premise is that controlled mechanical stress triggers a regenerative endothelial response and promotes new vessel formation. PEMF produces no pressure wave at all, but a low-intensity magnetic field directed at inflammation, perfusion and tissue repair.

The distinction is not semantic: it is the reason a figure measured with one technology cannot be attached to the other, and it is the single most common error on marketing pages in this category.

What Did the Largest and Most Recent Review of Micro-Energy Treatment Find?

That these treatments work, that the effect lasts up to a year, and that no energy type — including electromagnetic fields — significantly outperformed another. The work, published in the World Journal of Men's Health in September 2025 by the Department of Urology at Tongji Hospital, Huazhong University of Science and Technology in Wuhan, enrolled 32 randomized controlled trials with 1,986 patients and searched PubMed, Web of Science and Embase up to April 2025. The treatment group showed better erectile function than control at 1, 3, 6 and 12 months (p<0.05), and subgroup analysis found no significant difference between energy types, course lengths or device settings (PubMed 41047356).

Three further findings in that paper are the most directly applicable to a clinic. Treatment twice weekly was superior to once weekly (p<0.05), and the authors recommend a course of no more than four weeks. Combining micro-energy treatment with other basic therapies enhanced efficacy (p<0.05) — the principle of combination is itself evidence-supported, even though the specific pairing of shockwave with PEMF has not been tested separately. And one caveat worth stating to the right patient: vasculogenic ED responded better than neurogenic ED (p<0.05). Comorbidities and prior responsiveness to PDE5 inhibitors did not influence efficacy — so a man for whom the tablets did not work remains a reasonable candidate.

How Strong Is a Pulsed Electromagnetic Field on Its Own?

The best sham-controlled evidence on a pulsed electromagnetic field in erectile function is larger than the equivalent evidence on shockwave — and both are small. A 2024 triple-blind randomized trial run across two centres at Imam Abdulrahman Bin Faisal University and King Fahd Hospital of the University in Saudi Arabia enrolled 52 men with multiple sclerosis and erectile dysfunction, randomized to a pulsed electromagnetic field plus pelvic floor exercise or to sham plus the same exercise, for three weeks. The treatment group improved more on the IIEF-EF by a mean difference of 6.9 points (p<0.001), and also on SHIM, erection hardness and fatigue (PubMed 39685520).

The comparison that gives that number its meaning: the July 2025 Cochrane review, covering 21 randomized trials and 1,357 men, found shockwave improved IIEF-EF by 3.89 points in the short term (95% CI 2.89 to 4.89) — and states explicitly that below the 4-point minimal clinically important difference, that effect may not be meaningful to the patient. Long term, shockwave did reach 5.25 points (95% CI 2.47 to 8.04), but across only five studies and 276 participants, and the certainty of all outcomes was rated low, partly because several of the included studies were funded by device manufacturers (PubMed 40654049). Said plainly: one trial of 52 men is not equivalent to 21 trials of 1,357 men. But the claim that the electromagnetic field is the weaker technology of the pair is not supported by the evidence — the two have simply not been studied at the same scale.

Three Naming Traps to Know Before Reading Any Number in This Field

Two of them appear on almost every marketing page in the category. First, some shockwave devices generate the wave with an electromagnetic coil, and in the literature these are called Electromagnetic Li-ESWT. That is a pressure wave, not magnetic field therapy, and its results belong in the shockwave column. Second, extracorporeal magnetic innervation (ExMI) is a high-intensity field that drives active muscular contraction — PEMF does not do this, and the data do not transfer. Third, EMTT (magnetotransduction therapy) is a separate commercial technology marketed alongside shockwave: as of September 2026 there is not a single clinical publication indexed in PubMed on EMTT in erectile dysfunction, so any success rate attributed to it comes from clinic marketing material rather than from research.

What Did the Largest Review of Shockwave for ED Find — and Why Is the Conclusion Surprising?

A 2026 systematic review and meta-analysis conducted at the Department of Urology, Wan Fang Hospital, Taipei Medical University, together with Cochrane Taiwan, pooled 19 randomized controlled trials and reached a conclusion most readers do not expect. The work was pre-registered in PROSPERO. The positive finding: statistically significant improvement in IIEF scores at 1-month, 3-month and 6-month follow-up.

The finding that changes the interpretation: the majority of included studies did not reach the Minimal Clinically Important Difference, and the authors write plainly that on the currently available evidence it remains unclear whether Li-ESWT provides a clinically meaningful benefit in erectile dysfunction (PubMed 41894473). Meta-regression in the same paper found that treatment frequency and pulse count per course were associated with the size of the response, but did not permit a recommended protocol.

The gap between statistical significance and an improvement the patient actually feels is the central point of this article, and it applies to both technologies equally.

Where Does Shockwave Rank Against the Other Non-Pharmacological Options?

A 2026 network meta-analysis of 31 randomized trials and 1,874 participants ranked five non-pharmacological interventions against each other — and shockwave was not first. The study, from Sichuan Provincial People's Hospital and the Sichuan Academy of Medical Sciences, was pre-registered in PROSPERO and compared electrical stimulation, exercise, Li-ESWT, acupuncture-based therapies and hyperbaric oxygen.

On the IIEF-5, electrical stimulation combined with exercise led by a wide margin: a mean difference of 6.81 points versus sham/placebo (95% CI 3.50 to 10.12, SUCRA 98.1%, high-certainty evidence). Electrical stimulation alone showed 2.86 points (95% CI 0.86 to 4.85, high certainty). Li-ESWT offered only a modest benefit — a mean difference of 0.65 points, with a confidence interval touching zero (95% CI 0.00 to 1.29) (PubMed 41649306). On one secondary outcome shockwave did stand out: combined with exercise it led on peak systolic velocity (MD 7.33). No serious adverse events occurred in any arm.

This figure appears here in full precisely because it does not flatter the technology under discussion — and a clinic that presents it is the one a patient believes on every other number.

Does the Combination Actually Make the Difference?

Two entirely different "combinations" have to be separated here, because the evidence behind them is not comparable.

First combination — shockwave with medication. A 2026 meta-analysis from the University of Milan and University College London examined 8 studies with 553 patients and found no significant overall difference between combination therapy and monotherapy. In subgroup analysis, however, PDE5 inhibitors combined with shockwave were superior to shockwave alone (SMD 0.61, 95% CI 0.13 to 1.09, p=0.013), with a larger advantage in vasculogenic (SMD 0.65, p<0.001) and diabetic cases (SMD 1.05, p<0.001) — with a high risk of bias owing to study quality (PubMed 40797370).

Second combination — shockwave with a pulsed magnetic field. Here exactly one prospective randomized trial exists, from the National Medical Research Center for Rehabilitation and Balneology in Moscow, with 40 men with vasculogenic erectile dysfunction split into two groups of 20. The shockwave-only group improved on the IIEF-5 by 20.7%; the group receiving shockwave together with a pulsed magnetic field improved by 34.1% (p<0.05), and on the Goldstein erection hardness scale by 30.9% versus 20.5% (PubMed 32592571).

Three caveats must be stated alongside that number, or it becomes a promise. First, the application site differs: the magnetic field in that trial was delivered transcerebrally — to the head — not to the pelvis or perineum, so it is not the protocol a clinic actually runs. Second, the size: 40 participants, a single centre, no sham-controlled arm. Third, not one trial has tested local PEMF combined with shockwave. The honest conclusion: the combination has a positive early signal and a plausible mechanistic rationale, and it does not have an evidence base that justifies a promise to a patient.

What Is Actually Known About PEMF Alone in Sexual Function?

Three studies measured this directly, and only one — the smallest — showed improvement in erection. The only trial that set erection as its primary endpoint is a double-blind placebo-controlled study from Germany with just 20 participants, in which 80% of the active group reported improved erection intensity and duration versus 30% on placebo (PubMed 12008861).

Against it, two larger and more recent works that measured erection as a secondary endpoint found no significant improvement: a meta-analysis of 8 randomized trials and 636 patients found only 0.81 points on the IIEF-5, with a confidence interval crossing zero (95% CI -0.34 to 1.95, p=0.17) (PubMed 39262719); and an interventional study at Sapienza University of Rome delivering perineal PEMF to 27 men found a significant reduction in prostate volume and improved urinary symptoms, while reporting explicitly no change in gonadal hormones or sexual function (PubMed 32090492).

The difference is not a contradiction but a difference of aim: the 2002 trial targeted erection, while the other two treated pelvic pain and the prostate and measured erection as a secondary outcome.

When Might the Combination Be Relevant — and When Not At All?

When the stated target is pain, urinary symptoms and the myofascial component, and erection is presented as a possible outcome rather than the thing being sold. Three scenarios that are clinically reasonable:

1. A man with chronic pelvic pain / chronic prostatitis (CP/CPPS) who also has comorbid erectile dysfunction — here a meta-analysis of 9 randomized trials did find that shockwave improved erectile function (SMD 0.80, 95% CI 0.31 to 1.28) and reduced NIH-CPSI scores, albeit at low GRADE certainty for efficacy (PubMed 42275556).
2. A patient already in a shockwave series who presents in parallel with other musculoskeletal pain — where the PEMF evidence base is broader, and the combination addresses two problems rather than inflating one promise.
3. A patient who prefers a non-pharmacological path or cannot take PDE5 inhibitors, provided urological follow-up continues alongside.

And equally — when not. New-onset erectile dysfunction, particularly with chest pain, shortness of breath or poorly controlled diabetes, requires cardiovascular assessment before any physical treatment — erectile dysfunction is a recognised early marker of vascular disease, and any treatment that delays that assessment is the real risk here. An active electronic implant — pacemaker, implanted defibrillator, neurostimulator or implanted drug pump — is an absolute contraindication to PEMF. Active malignancy in the treatment field, active infection and unstable anticoagulation all require prior physician approval.

Comparison: Shockwave, PEMF, and the Combination

Operational Experience Across the PainFree Network

From experience implementing the technology across 70+ Israeli clinics serving a population of 9M — now expanding to the Philippines — the obstacle in this indication is almost never technical but a matter of expectation: the patient hears "combination" and translates it into "double the result." Three points recur in the field:

1. Record the IIEF-5 at the start and end of the series, in writing. The questionnaire is free and takes two minutes. A clinic that records it knows whether it helped; a clinic that does not is arguing with the patient's memory at the end of a series he paid for.
2. Define in advance what the target is and what would be a bonus. When the stated target is pain and urinary symptoms, an improvement in erection is experienced as a gain. When the stated target is erection, the very same partial result is experienced as a failure.
3. Ask about cardiovascular follow-up on the intake form, not in conversation. Date of last check, blood pressure and glucose values, regular medications. This is not bureaucracy — this is the population in which that question finds a problem the patient did not know he had.

These are operational observations from field implementation and are not clinical trial results. The results themselves appear in this article only from the linked sources.

What This Means for Clinic Owners and Investors

This is an audience that searches quietly, pays out of pocket, and stays in long treatment series — and in which credibility is a commercial asset rather than only a value. The role of PEMF here is neither to replace shockwave nor to replace urological follow-up, but to extend the clinic's toolkit: particularly for patients presenting with pelvic pain, comorbid musculoskeletal pain, or contraindications to pharmacological treatment. The system allows hands-free treatment, so the therapist is not tied to the bed for the session, and it integrates alongside shockwave, manual therapy and pelvic floor training. In the Philippines market, a treatment session in this category is typically priced at ₱1,500–₱2,500. The clinics that succeed in this indication are distinguished not by the device but by the protocol in front of it: a documented medical assessment, an implant screen, and a goal defined in advance.